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Immunohistochemistry
Mice bearing BxPC3 tumor xenografts were treated with 50 or 150 mg/kg GSK2656157 twice daily for 3 weeks. Four hours following the last dose, tumors were harvested and fixed in 10% neutral buffered formalin for 24 h then paraffin embedded. Sections were cut (6 μM) and immunohistochemical analysis was carried using the Ventana Discovery XT system (Ventana/Roche Tuscon, Az). Briefly, sections were deparaffinized, hydrated and loaded on the Discovery XT. Antigen retrieval was performed using Tris based (EDTA) buffer solution, CCL 
Magnetic Resonance Imaging (MRI)
Twelve week old female nude mice bearing subcutaneous BxPC3 tumor xenografts were treated with vehicle (n=6) or 150 mg/kg GSK2656157 (n=12) (PO, BID for 14 days). MRI was performed pre-treatment (day 0), day 7, and day 14 post-treatment using a 9.4T/30 cm Bruker system (Bruker Biospin GmbH, Germany). Mice were anesthetized with continuously inhaled isoflurane (1.5-2%) and a constant body temperature of 37°C was maintained using a circulating-water heating system. Respiration was monitored using a respiratory sensor (SA Instruments, Inc, Stony Brook, NY) placed on the abdomen of the animal. Image processing and data analysis were performed on a voxel-by-voxel basis by external observer (Mango Solutions, London, UK). All images were stored in ANALYZE format and were converted to NIfTI for data processing. Two axial slices of each DCE acquisition were analyzed; regions of interest (ROIs) that cover the tumor were defined and the T1 relaxation rate was calculated from the T1 map. The signal intensities from the dynamic acquisition (DCE) were converted into gadolinium contrast-agent concentration to calculate the K Bars represent densitometric analysis of phospho-PERK, normalized to vehicle treated control (mean ± SD).
Supplementary Figure 2. Specificity of phospho-PERK antibody in mouse cells
Murine LL/2 cells were pre-treated with different concentrations of GSK2656157 for 1 h, followed by thapsigargin for an additional 1 h. Cell lysates were analyzed by Western blot for various antigens using antibodies for actin (Sigma), phospho-PERK Thr980, total PERK, phospho-eIF2α Ser51 and total eIF2α (Cell Signaling Technologies).
Supplementary Figure 3. Effect of PERK inhibitor on RNA expression in tumor xenografts
Mice bearing BxPC3, HPAC or RPMI-8226 tumor xenograft were treated twice daily with vehicle or GSK2656157 at 150 mg/kg for 2.5 days. On day 3, tumors were harvested after the single dose and RNA expression was analyzed using RT-PCR. Data represent RNA expression of each gene normalized to actin expression (mean +/-SD, n=4 mice/group). 
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